Essam, Mohamed
Hamid, Eman
Abushady, Eman
El-Balkimy, Mahmoud
Antonini, Angelo
Shalash, Ali http://orcid.org/0000-0001-7012-5907
Funding for this research was provided by:
Ain Shams University
Article History
Received: 26 August 2023
Accepted: 7 February 2024
First Online: 20 February 2024
Declarations
:
: The study was approved by the Ethical Review Committee, Ain Shams University in accordance with the Helsinki Declaration and was registered in clinical trials.gov, NCT 04182399. Patients were informed of the objectives, procedures and possible benefits and risks of the study and provided written voluntary consent, which also allowed patients to withdraw from the study at any time without any consequences.
: The authors declare no competing interests.
: Angelo Antonini has received compensation for consultancy and speaker-related activities from UCB, Britannia, AbbVie, Zambon, Bial, Ever Pharma, Theravance Biopharma, Roche, General Electric, Medscape. He receives research support from Chiesi Pharmaceuticals, Lundbeck, Bial, Movement Disorders Society, Horizon2020 Grant 825785, Horizon2020 Grant 101016902, Ministry of Education University and Research (MIUR) Grant ARS01_01081 and Cariparo Foundation. Other authors have no financial conflicts of interest to disclose, with no financial support or funding.